These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 3965285

  • 21. Multidrug therapy in leprosy.
    Manglani PR, Arif MA.
    J Indian Med Assoc; 2006 Dec; 104(12):686-8. PubMed ID: 17474286
    [Abstract] [Full Text] [Related]

  • 22. Can leprosy be eradicated with chemotherapy? An evaluation of the Malta Leprosy Eradication Project.
    Jacobson RR, Gatt P.
    Lepr Rev; 2008 Dec; 79(4):410-5. PubMed ID: 19274987
    [Abstract] [Full Text] [Related]

  • 23. Combined therapy in principle and practice for the control of dapsone resistance.
    Rees RJ.
    Lepr Rev; 1978 Jun; 49(2):97-100. PubMed ID: 661485
    [No Abstract] [Full Text] [Related]

  • 24. Kellersberger Memorial Lecture 1978. Leprosy control--present position and future prospects.
    Browne SG.
    Ethiop Med J; 1978 Oct; 16(4):169-78. PubMed ID: 744197
    [No Abstract] [Full Text] [Related]

  • 25. Srategy of leprosy control.
    WHO Chron; 1978 May; 32(5):193-9. PubMed ID: 664625
    [No Abstract] [Full Text] [Related]

  • 26. Priorities for the future and prospects for leprosy control.
    Becx-Bleumink M.
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):82-101. PubMed ID: 8326185
    [No Abstract] [Full Text] [Related]

  • 27. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR, Shrestha K, Pandey B, Walker SL.
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The treatment of leprosy in Papua New Guinea.
    Reé GH.
    P N G Med J; 1982 Sep; 25(3):142. PubMed ID: 6961638
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Multiple drug therapy: implications for field work and training at ALERT (All Africa Leprosy and Rehabilitation Training Centre).
    Becx-Bleumink M.
    Lepr Rev; 1986 Dec; 57 Suppl 1():69-80. PubMed ID: 3586836
    [No Abstract] [Full Text] [Related]

  • 36. [Evaluation 7 to 9 years later of trials of polychemotherapy carried out in Senegal in patients with leprosy].
    Millan J, Faure I, Diouf B, Languillon J.
    Acta Leprol; 1985 Dec; 3(2):95-102. PubMed ID: 3907256
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Combined therapy of leprosy in Bhutan.
    Samuel NM, Samuel S.
    Indian J Lepr; 1984 Dec; 56(3):647-52. PubMed ID: 6549335
    [No Abstract] [Full Text] [Related]

  • 39. Dihydropteroate synthase mutations in the folP1 gene predict dapsone resistance in relapsed cases of leprosy.
    Cambau E, Carthagena L, Chauffour A, Ji B, Jarlier V.
    Clin Infect Dis; 2006 Jan 15; 42(2):238-41. PubMed ID: 16355335
    [Abstract] [Full Text] [Related]

  • 40. Fixed duration MDT in paucibacillary leprosy (classical and modified).
    Nadkarni NJ, Grugni A, Kini MS.
    Int J Lepr Other Mycobact Dis; 1993 Mar 15; 61(1):25-8. PubMed ID: 8326177
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.